A randomized controlled trial of amyloid positron emission tomography results disclosure in mild cognitive impairment. Issue 9 (26th June 2020)

• Record Type: Journal Article
• Authors: Lingler, Jennifer H.; Sereika, Susan M.; Butters, Meryl A.; Cohen, Ann D.; Klunk, William E.; Knox, Melissa L.; McDade, Eric; Nadkarni, Neelesh K.; Roberts, J. Scott; Tamres, Lisa K.; Lopez, Oscar L.
• Is Part Of: Alzheimer's & dementia. Volume 16:Issue 9(2020)
• Page Start: 1330
• Page End: 1337
• Publication Date: 2020-06-26
• Subjects: amyloid positron emission tomography -- biomarker disclosure -- caregiving -- ethics -- mild cognitive impairment; Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1002/alz.12129
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Introduction: Recent studies suggest that Alzheimer's disease (AD) biomarker disclosure has no discernable psychological impact on cognitively healthy persons. Far less is known about how such results affect symptomatic individuals and their caregivers. Methods: Randomized controlled trial of 82 mild cognitive impairment (MCI) patient and caregiver dyads (total n = 164) to determine the effect of receiving amyloid positron emission tomography results on understanding of, and perceived efficacy to cope with, MCI over 52 weeks of follow‐up. Results: Gains in the primary outcomes were not consistently observed. Amyloid negative patients reported greater perceived ambiguity regarding MCI at follow‐up, while moderate and sustained emotional distress was observed in patients, and to a lesser extent, caregivers, of those who were amyloid positive. There was no corresponding increase in depressive symptoms. Discussion: These findings point to the possibility that both MCI patients and caregivers may need emotional support after the disclosure of amyloid scan results.